Abstract
Reversible cholinesterase inhibitors in clinical use can be divided into peripherally and centrally acting compounds. The peripherally acting compounds, neostigmine, pyridostigmine and edrophonium are all quaternary ammonium compounds and are used for the reversal of neuromuscular blockade following anesthesia and in patients with myasthenia gravis (Aquilonius and Hartvig, 1988). The centrally acting compounds physostigmine and 1,2,3,4-tetrahydro-9-aminoacridine (THA), have been used in the management of pain (Hartvig et al., 1989a) and in the treatment of several neurological or psychiatric diseases. Renewed interest in the centrally active drugs has arisen following positive reports on symptom alleviation in patients with different types of dementia (Summers et al., 1986, for review see Håkansson, 1990).
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Aquilonius SM and Hartvig P (1986): Clinical pharmacokinetics of cholinesterase inhibitors. Clin Pharmacokinet 11:236–249.
Askmark H, Aquilonius SM, Gillberg PG, Hartvig P, Hilton-Brown P, Lindström B, Nilsson D and Stålberg E (1991): Functional and pharmacokinetic studies of tetrahydroaminoacridine in patients with amyotrophic lateral sclerosis. Acta Neurol Scand 82:253–258.
Brufani M, Castellano C, Marta M, Oliverio A, Pagella PG, Pavone F, Pomponi M and Rugarli PL (1987): A long-acting cholinesterase inhibitor affecting neural and behavioral processes. Pharmacol Biochem Behav 26:625–629.
De Sarno P, Pomponi M, Giacobini E, Tang XC and Williams E (1989): The effect of heptyl-physostigmine, a new choline esterase inhibitor on the central cholinergic system of the rat. Neurochem Res 14:971–977.
Forsyth DR, Wilcock GK, Morgan RA, Truman CA, Ford JM and Roberts CJC (1989): Pharmacokinetics of tacrine hydrochloride in Alzheimer’s disease. Clin Pharmacol Therap 46:634–641.
Hartvig P, Askmark H, Aquilonius SM, Wiklund L and Lindström B (1990): Clinical pharmacokinetics of intravenous and oral 9-aminotetrahydroacridine, Tacrine. Europ J Clin Pharmacol 38:259–263.
Hartvig P, Gillberg PG, Gordh T Jr and Post C (1989a): Cholinergic mechanism in pain and analgesia. Subtypes of Muscarinic receptors IV, Trends in Pharmacological Sciences, Suppl. pp. 75-79.
Hartvig P, Lindström B, Pettersson E and Wiklund L (1989b): Reversal of postoperative somnolence using a two rate infusion of physostigmine. Acte Anaesthesiol Scand 33:681–685.
Hartvig P, Pettersson E, Wiklund L and Lindström B (1991): Pharmacokinetics and effects of 9-amino-l,2,3,4,-tetrahydroacridine, Tacrine in the immediate postoperative period. J Clin Anesthes 3:137–142.
Hartvig P, Wiklund L and Lindström B (1986): Pharmacokinetics of physostigmine after intravenous, intramuscular and subcutaneous administration in surgical patients. Acta Anaesthesiol Scand 30:177–182.
Häkansson L (1990): Modulation of acetylcholine release in brain. Doctoral thesis from the Faculty of Pharmacy, University of Uppsala No. 72, Lindbergs grafiska, Uppsala, Sweden.
Mihailova D, Yamboliev I, Zhivkova Z, Tencheva J and Jovovich V (1989): Pharmacokinetics of galanthamine hydrobromide after single subcutaneous and oral doses in humans. Pharmacology 39:50–58.
Nyback H, Nyman H, Öhman G, Nordgren I and Lindström B (1988): Preliminary experiments and results with THA for the amelioration of symptoms of Parkinson’s disease. In: Current Research on Alzheimer Therapy, Giacobini E and Becker R, eds. London: Taylor and Francis, pp. 231–236.
Peterson J, Gordh TE, Hartvig P and Wiklund L (1986): A double-blind trial of the analgesic properties of physostigmine in postoperative patients. Acta Anaesthesiol Scand 30:283–288.
Puri SK, Hsu R, Ho I and Lassman HB (1988): Single-dose safety, tolerance and pharmacokinetics of HP 029 in elderly men: A potent Alzheimer agent. Curr Ther Res 44:766–780.
Summers WK, Majovski LV, March SM, Tachiki K and Kling A (1986): Oral tetrahydroaminoacridine in long term treatment of senile dementia. New Engl J Med 315:1241–1245.
Thomsen T, Bickel U, Fischer JP and Kewitz H (1990): Galanthamine hydrobromide in a long-term treatment of Alzheimer’s disease. Dementia 1:46–51.
Unni LK, Becker RE, Hutt V and Imbimbo BP (1990): Inhibition of acetylcholin esterase and butyrylcholinesterase after oral administration of heptastigmine in healthy volunteers. Eur J Pharmacol 183:536.
Whelpton R (1983): Analysis of plasma physostigmine concentrations by liquid chromatography. J Chromatogr 272:216–220.
Westra P, van Thiel MJS and Vermeer GA (1986): Pharmacokinetics of galanthamine (a long acting anticholinesterase drug) in anesthetized patients. Brit J Anesth 58:1303–7.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1991 Springer Science+Business Media New York
About this chapter
Cite this chapter
Hartvig, P., Wiklund, L., Aquilonius, S.M., Lindström, B. (1991). Clinical Pharmacokinetics of Centrally Acting Cholinesterase Inhibitors. In: Becker, R., Giacobini, E. (eds) Cholinergic Basis for Alzheimer Therapy. Advances in Alzheimer Disease Therapy. Birkhäuser, Boston, MA. https://doi.org/10.1007/978-1-4899-6738-1_8
Download citation
DOI: https://doi.org/10.1007/978-1-4899-6738-1_8
Publisher Name: Birkhäuser, Boston, MA
Print ISBN: 978-1-4899-6740-4
Online ISBN: 978-1-4899-6738-1
eBook Packages: Springer Book Archive